Exicure(US:XCUR)2026-03-25 20:32Financial Performance - The company reported a net loss of $4.9 million for 2025, a reduction from a net loss of $9.7 million in 2024, largely due to a $6.0 million gain from lease liability reversal[8] - Total revenue for 2025 was $0, a decrease from $500,000 in 2024, reflecting a significant decline in operational performance[17] - Total operating expenses for 2025 were $4.2 million, down from $12.7 million in 2024, primarily due to reduced litigation and impairment losses[17] Cash and Liquidity - Cash and cash equivalents decreased to $3.7 million as of December 31, 2025, from $12.5 million as of December 31, 2024, indicating potential liquidity issues for the next 12 months[3] - The company has engaged in significant cost reductions and requires substantial additional financing in the short term to continue operations[9] Expenses - Research and development expenses for 2025 were $3.3 million, a significant increase from $0 in 2024, due to activities following the acquisition of GPCR Therapeutics USA Inc.[4] - General and administrative expenses rose to $6.8 million in 2025, up from $5.4 million in 2024, primarily due to costs associated with the acquisition and integration of GPCR USA[5] Shareholder Considerations - The weighted-average basic and diluted common shares outstanding increased to 6,297,094 in 2025 from 2,043,278 in 2024, indicating a potential dilution of shares[17] - The company is exploring strategic alternatives to maximize stockholder value following its restructuring and acquisition activities[10] Lease and Gains - The company recognized a $6.0 million gain from the early termination of its Chicago office lease, effective January 31, 2025[6]